Cadila Healthcare has received tentative approval from the US Food and Drug Administration (USFDA), for the oral iron chelator.

The approval is for Deferasirox, which is an oral iron chelator. The purpose of Deferasirox is to reduce chronic iron overload in patients, who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.

Read EquityPandit’s Technical Analysis of Nifty Pharma